Assesses safety and efficacy of IVIg 10% dosing in pediatric CIDP patients, indicating optimal treatment approaches.
This phase III study aims to evaluate the safety and efficacy of different IVIg 10% dose regimens in pediatric CIDP patients.
No takes yet. Share an insight, caveat, or question.
Thomas et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: